Abstracts after adjusting for age, gender, gout treatment, comorbidities, and medication use. RESULTS: We identifi ed 4821 AMI cases of which 1410 were women. The adjusted odds ratio (OR [95% CI]) of AMI among women with gout was 1.62 (1.21-2.16), higher than the adjusted OR for men (1.12 [0.99-1.26]; p-value for interaction 0.01). When we combined both women and men in our analyses, we found an overall adjusted OR of 1.15 (1.06-1.25). CONCLUSIONS: Using population-based data, we found a 62% increased risk for AMI among elderly women with gout, and a 15% increased risk for elderly gout patients overall. The association between hyperuricemia, a known precursor to gout, and cardiovascular disease provides a potential explanation for our fi ndings. Gender differences in serum uric acid levels and metabolism may further explain the difference in risks between women and men. Findings provide support for the aggressive management of cardiovascular risk factors in gout patients. OBJECTIVES: In clinical studies, comorbidity measurement refers to assessment of total burden of illnesses across multiple health conditions unrelated to the patients' disease under study. In non-randomized clinical studies and epidemiology studies, adjustment for comorbidity is often undertaken to ensure outcomes are not directly affected by comorbidities. This analysis compared 3 measurements of comorbidities and their effects on physical function and quality of life with data from a randomized controlled trial of adalimumab in ankylosing spondylitis (AS). METHODS: Data were derived from the Adalimumab Trial Evaluating Long-Term Effi cacy and Safety in AS (ATLAS). Comorbidity indices at baseline were calculated as Chronic Disease Score (CDS), number of separate prescription medications (prescription count), and number of concurrent illnesses (concurrent illness count). Medications taken specifically for the treatment of AS were excluded from the CDS and prescription medication count calculations. Univariate associations between each of the 3 indices and a physical function index (SF-36 PCS) and AS disease-specifi c quality of life (ASQOL) at Week 12 were assessed. Correlations with each comorbidity measurement were ascertained. Model selection (Alkaike's Information Criterion [AIC]) was used to identify the best comorbidity measure for predicting SF-36 PCS and ASQOL. RESULTS: A total of 315 patients were included in the analysis. Their mean age was 42.2 years, and most were male (74.9%). At the univariate level, all 3 indices were signifi cant predictors of SF-36 PCS score (p 0.02), However, only CDS and prescription medication count were signifi cantly associated with ASQOL at Week 12. All 3 indices were well-correlated with each other (range 0.750-0.917). The AIC model demonstrated that CDS was the best predictor of SF-36 PCS and ASQOL. Prescription count was the second-best ranked measure for both outcomes. CONCLUSIONS: The CDS is a suitable measure for comorbidity adjustment in examining physical function and quality of life for AS patients.
PMS4 RISK FACTORS FOR INCIDENT GOUT AMONG WOMEN: A PROSPECTIVE STUDY
Bhole V 1 , De Vera MA 2 , Rahman MM 1 , Choi HK 2 1 Arthritis Research Centre of Canada, Vancouver, BC, Canada, 2 UBC School of Population & Public Health, Vancouver, BC, Canada OBJECTIVES: Despite increasing incidence and substantial prevalence of gout among women, particularly among elderly, no prospective data on the risk factors for gout are available among women. We prospectively evaluated purported risk factors for the risk of incident gout among women and compared them with men. METHODS: Using data from the Framingham Heart Study, we prospectively examined over a 52year period (1948-2001) the relation between prior serum uric acid levels and the risk of incident gout in 2,470 women and 1,951 men. We used Cox proportional hazards models to estimate the relative risk for incident gout by uric acid level after adjusting for age, body mass index, blood glucose level, blood cholesterol level, hypertension, use of diuretics, alcohol consumption, educational level and menopausal status. RESULTS: Over a 28-year median follow-up, we documented 304 incident cases of gout, 104 among women. The incidence rates of gout increased with increasing serum uric acid levels, similar to men. For uric acid levels of 5.0, 5.0-5.9, 6.0-6.9, 7.0-7.9 and 8.0 mg/dL the incidence rates of gout per 1000 person-years were 0.81, 1.42, 1.83, 6.75, and 13.09, respectively (p for trend 0.0001). The multivariate relative risk (95% CI) for incident gout for every 1.0 mg/dL increase in serum uric acid level was 1.57 (1.38-1.78) among women and 1.52 (1.36-1.71) among men. Other significant predictors of gout in women were age, obesity, hypertension, blood glucose level and diuretic use. CONCLUSIONS: These prospective data indicate that higher levels of serum uric acid increase the risk of gout among women in a graded manner, similar to men, and support the notion that serum uric acid is a reliable surrogate marker and precursor of incident gout among women as well. Age, obesity, hypertension, blood glucose level and diuretic use were associated with the risk of incident gout among women.
PMS5 FACTORS INFLUENCING THE LENGTH OF STAY AND TOTAL CHARGES FOR PEDIATRIC PATIENTS DIAGNOSED WITH OSTEOMYELITIS
Dorwart JL J University of Louisville, Louisville, KY, USA OBJECTIVES: Osteomyelitis is an infection of the bone caused by an untreated injury. Osteomyelitis can also come from an infection from another part of the body, such as a urinary tract infection that can spread to the bone through the blood. The purpose of this study is to determine what factors can infl uence a pediatric patient's stay in the hospital when the patient has a diagnosis of osteomyelitis. METHODS: In order to look at the length of stay and total charges for the patient's stay in the hospital, we used table analysis, summary statistics, one way frequency, kernel density, logistic regression, and linear regression. Kernel density examines the entire population distribution. Logistic regression gives a prediction of the probability of occurrence. Linear regression analyzes the effect of one variable on another. The data were taken from the 2005 National Inpatient Sample with a total of 3972 patients; 1971 have osteomyelitis and the remaining 2001 patients form a control group. RESULTS: The average length of stay in the hospital was about eight days. For patients who had osteomyelitis, the peak value of total charges was around $10,000, and those who did not have the disease had a peak value of total charges of around $5,000. The variables that are signifi cant on total charges are died, length of stay, race, bacterial infection, episodic mood disorders, arthrocentesis, magnetic resonance, incision, excision, and division, other incision with drainage, injection of antibiotic, and spinal tap. CON-CLUSIONS: Generally, patients who have osteomyelitis have a longer hospital stay and a higher bill compared to those that do not. The procedures performed on a patient infl uence their length of stay and total charges. Length of stay is infl uenced more by invasive procedures and total charges are infl uenced on length of stay and the number of procedures performed.
PMS6

DEVELOPMENT OF TESTS FOR DIAGNOSIS OF RHEUMATOID ARTHRITIS
Schiff L 1 , Foster T 1 , Creeden J 2 , Gartemann J 2 , Hsieh J 2 , Pashos CL 1 1 Abt Bio-Pharma Solutions, Inc., Lexington, MA, USA, 2 Roche Diagnostics, Ltd, Rotkreuz, Switzerland OBJECTIVES: New therapeutic options for rheumatoid arthritis (RA) have shifted the focus of treatment to early, aggressive intervention aimed at preventing further joint damage. However, early diagnosis has proved challenging, and recent efforts have been made to identify new diagnostic tests. We systematically reviewed the literature to assess the current status of tests for early diagnosis of RA. METHODS: We searched English-language MEDLINE-indexed publications in the 5 years prior to August 2008 concerning tests and biomarkers for early diagnosis of RA. We also searched non-MEDLINE-indexed sources such as organization websites, meeting abstracts, and governmental publications using the same keywords. RESULTS: We identifi ed 94 primary studies from MEDLINE pertaining to tests or biomarkers for early diagnosis of RA. Non-MEDLINE sources yielded an additional 56 articles for a total of 150 reviewed for this study. In practice, no single test has proved suffi ciently sensitive and specifi c for the diagnosis of RA. Tests currently in use, including the acute phase biomarkers erythrocyte sedimentation rate and C-reactive protein and the autoantibody rheumatoid factor (RF), are relatively nonspecifi c for RA. Recent efforts have focused on identifying new biomarkers with greater RA specifi city. These include many autoantibodies, immune system biomarkers, and biomarkers of collagen breakdown and bone erosion. The autoantibody anti-cyclic citrullinated peptide (anti-CCP) offers high specifi city, but lower sensitivity than RF. Newer-generation anti-CCP assays provide improved sensitivity over fi rst-generation anti-CCP assays, but sensitivity still precludes their use as sole diagnostic tests for RA. The clinical utility of anti-CCP tests can be improved by combining with other assays such as RF, and provide particular value in predicting the development of persistent and/or erosive RA. CONCLUSIONS: Newer generations of the autoantibody anti-CCP assay offer high specifi city for RA and appear promising as a diagnostic test in combination with other tests with greater sensitivity. Patients were required to have a minimum of 12-months of continuous records prior to the index infl iximab date and were followed for up to 24-months after therapy initiation. Effectiveness was defi ned as reductions in joint pain, swelling, stiffness, and fatigue scores of 1 point (range from 0 to 10). Overall clinical improvement was measured as a combination of pain, swelling, stiffness, and fatigue scores. Wilcoxon Signed-Rank Tests were performed to test if there were statistically signifi cant changes from baseline. Also, biomarker test results, C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR), were collected and compared to the baseline results. RESULTS: A total of 266 infl iximab patients were identifi ed (72.9% female; average
PMS7 A 2-YEAR EVALUATION OF INFLIXIMAB'S EFFECTIVENESS IN THE TREATMENT OF RHEUMATOID ARTHRITIS IN ACTUAL PRACTICE
